ArticleJournal of gastrointestinal oncology2026
PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The conclusions regarding programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) expression and its role as a predictive biomarker for treatment efficacy had been inconsistent in previous clinical trials of PD-1 monoclonal antibodies therapy for hepatocellular carcinoma (HCC). Therefore, this study aimed to analyze the expression of PD-1/PD-L1 in HCC patients treated with PD-1 in real-world settings and to evaluate its predictive value for treatment outcomes. Methods: A retrospective study was conducted on 59 pathologically confirmed HCC patients. PD-1/PD-L1 expression in tumor tissues was assessed via immunohistochemical staining. Clinical characteristics, laboratory parameters, pathological features, and therapeutic outcomes were compared between two groups. Results: Among 59 patients, 12 (20.33%) were PD-1-positive and 18 (30.51%) were PD-L1-positive. Compared with the PD-1-negative group, the PD-1-positive group exhibited a higher incidence of lymph node metastasis (41.7% Conclusions: PD-1/PD-L1 expression in HCC tissues is associated with distinct clinicopathological features but demonstrates no significant predictive value for anti-PD-1 therapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.